Vancouver, BC. On August 24, 2018, the Office of Controlled Substances (OCS), Health Canada granted Medipure Pharmaceuticals Inc. a full Level 6 Dealer's License for Controlled Substances pursuant to the Controlled Drugs and Substances Act, subject to an annual renewal process.
This license allows Medipure to use various controlled substances for its pharmaceutical research and development activities. The license permits Medipure to possess, sell and transport more than 25 substances that include Cannabinoids, Nabilone, Morphine, Oxycodone, Codeine, Fentanyl, Diazepam, their precursors and derivatives. The license will allow Medipure to fortify its R&D-based pharma development capabilities, including ongoing projects targeting Opioid and Benzodiazepine replacement therapies for treating various central nervous system-related disorders.
Medipure’s research is focused on the body’s endocannabinoid system, a previously under-explored network of receptors throughout the body that plays a role in many biological and physiological functions. It’s focused on the development of a non-addictive prescription drug line to address chronic pain, anxiety and a variety of other conditions. The drug formulations could be an economical, non-addictive alternative to opioid and benzodiazepine-based prescription drugs that can be highly addictive with life-altering side effects.
For more information, please visit: http://medipurepharmaceuticals.com